Skip to content

13F-HR filed by Kynam Capital Management, LP

Kynam Capital Management, LP filed this 13F-HR for the quarter ended 2021-12-31, filed 2022-02-14, with 32 holding rows worth $187,071,000.

Accession
0001085146-22-000941
Filed
2022-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2021

A holdings report, 32 entries on the cover page, a total value of $187,071,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $187,071,000 with VALUE read as thousands by filing date, 13F file number 028-21939. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
GLOBAL BLOOD THERAPEUTICS USD37890U108COM992,949$29,064,000thousands by filing date
XENON PHARMACEUTICALS INC COM98420N105Stock670,093$20,934,000thousands by filing date
SYNDAX PHARMACEUTICALS INC87164F105COM956,165$20,930,000thousands by filing date
GOSSAMER BIO INC COM38341P102Stock1,016,857$11,501,000thousands by filing date
BIOGEN INC COM09062X103Stock40,000$9,597,000thousands by filing date
CELLDEX THERAPEUTICS INC NEW15117B202COM NEW226,726$8,761,000thousands by filing date
AMARIN CORP PLC023111206SPONS ADR NEW2,210,866$7,451,000thousands by filing date
VERA THERAPEUTICS INC92337R101COMMON STOCK253,449$6,772,000thousands by filing date
LIQUIDIA CORPORATION COM NEW53635D202Stock1,366,836$6,656,000thousands by filing date
AMICUS THERAPEUTICS INC03152W109COM573,699$6,626,000thousands by filing date
VIRIDIAN THERAPEUTICS INC92790C104COM287,934$5,692,000thousands by filing date
TRAVERE THERAPEUTICS INC89422G107COM182,103$5,652,000thousands by filing date
FATE THERAPEUTICS INC31189P102COM95,561$5,591,000thousands by filing date
VAXCYTE INC COM92243G108Stock211,483$5,031,000thousands by filing date
WAVE LIFE SCIENCES LTD SHSY95308105Stock1,494,594$4,693,000thousands by filing date
MERUS N VN5749R100COM122,158$3,885,000thousands by filing date
BURNING ROCK BIOTECH LTD12233L107SPONSORED ADS382,464$3,645,000thousands by filing date
ZOGENIX INC.98978L204Common Stock205,800$3,344,000thousands by filing date
OLEMA PHARMACEUTICALS INC68062P106COM293,799$2,750,000thousands by filing date
CENTESSA PHARMACEUTICALS PLC152309100SPONSORED ADS239,041$2,692,000thousands by filing date
SERES THERAPEUTICS INC81750R102COM304,901$2,540,000thousands by filing date
CABALETTA BIO INC12674W109COMMON STOCK644,583$2,443,000thousands by filing date
KRYSTAL BIOTECH INC COM501147102Stock34,816$2,435,000thousands by filing date
PUMA BIOTECHNOLOGY INC74587V107COMMON STOCK683,619$2,078,000thousands by filing date
AFFIMED N VN01045108COM364,033$2,009,000thousands by filing date
RADIUS HEALTH INC750469207COM NEW194,082$1,343,000thousands by filing date
COGENT BIOSCIENCES INC19240Q201COM150,000$1,287,000thousands by filing date
AKOUOS INC00973J101COM99,008$842,000thousands by filing date
NEOLEUKIN THERAPEUTICS INC64049K104COM147,000$709,000thousands by filing date
CATALYST BIOSCIENCES INC14888D208COM110,991$101,000thousands by filing date
GLOBAL BLOOD THERAPEUTICS USD37890U108COM100,000$15,000thousands by filing datecall
ALLAKOS INC01671P100COM74,500$2,000thousands by filing datecall

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001085146-22-000941this filing2022-02-14acceptance time not in the bulk data set